Pediatric Cancer Clinical Trial Finder
We believe that patients and families should have tools available to help make the search for treatments easier. For that reason, we’ve developed a Pediatric Cancer Clinical Trial Navigator for CAR T-cell therapy and other immunotherapy treatments. Use the filters to display relevant trials. Clicking on a card will allow you to access more detailed information, including contact information, for each clinical trial.
Genetic
Biological
Drug
Study of Anti-CD33 Chimeric Antigen Receptor-Expressing T Cells (CD33CART) in Children and Young Adults With Relapsed/Refractory Acute Myeloid Leukemia
U.S.
CA,
CO,
MD,
MA,
PA,
WA
Recruiting
Learn More
Genetic
Biological
Drug
CAR-20/19-T Cells in Pediatric Patients With Relapsed/Refractory B Cell ALL
U.S.
WI
Not yet Recruiting
Learn More
Genetic
Biological
Drug
Phase I CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults with Recurrent or Refractory B Cell Malignancies
U.S.
CA
Recruiting
Learn More
Genetic
Biological
Drug
Determine Efficacy and Safety of CTL019 in Pediatric Patients With Relapsed and Refractory B-cell ALL (ELIANA)
Canada
Australia
U.S.
CA,
GA,
MI,
MN,
MO,
NC,
OH,
OR,
PA,
TX,
UT,
WI
Europe
Japan
Active, not recruiting
Learn More
Genetic
Biological
Drug
Pilot Study of Non-Viral, RNA-Redirected Autologous T Cells in Patients With Refractory or Relapsed Hodgkin Lymphoma
U.S.
PA
Recruiting
Learn More
Genetic
Biological
Drug
Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia
U.S.
TN
Recruiting
Learn More
Active, not recruiting
Learn More
Genetic
Biological
Drug
Multi-virus CTLs Expressing CD19 Chimeric Receptors, CD19 Positive Malignancies Post SCT (MULTIPRAT)
U.S.
TX
Active, not recruiting
Learn More
Active, not recruiting
Learn More
Genetic
Biological
Drug
Her2 and TGFBeta CTLs in Treatment of Her2 Positive Malignancy (HERCREEM)
U.S.
TX
Completed
Learn More